Comparison of triple-dose single-donor platelet collection by the AmicusTM and the Trima Accel® blood-cell separators

Objective: The purpose of this study was to compare triple-dose single-donor platelet collection using AmicusTM and Trima Accel® blood-cell separators. Method: The same 25 donors underwent triple-dose single-donor platelet collection using the Amicus™ and Trima Accel® systems. The target endpoint was > 9.5 × 1011 platelets. Processing time, apheresis characteristics, donor safety, and satisfaction, were evaluated. In all, 18 donors completed the study; all of the resulting 36 donations were evaluated. Results: The collection ef ciency of both systems were not statistically different (80.25±10.64 vs. 76.63±6.06 %, p=0.228), the amount of whole blood volume processed was high (5274.50±874.86 vs. 4428.28±593.09 ml, p <0.001), and it used more infused ACD-A (593.56 ±92.74 vs. 521.17± 72.02 ml, p=0.010). The Trima Accel® process was faster (101.10±16.58 vs. 88.61±16.71 min, p=0.002). Most donors expressed satisfaction. The Trima Accel® system scored higher because its comparative speed (9.17 vs.9.22, p=0.805). After separation into blood constituents, all products had < 5.0 x106 (1.04±3.3 vs. 0.44 ±1.05 x 106/unit, p=0.372) residual white blood cells. No severe adverse reactions were noted with either of the instruments. Conclusion: Our experimental data showed that triple-dose platelet collection was safe using either system. The platelet yields satis ed American Association of Blood Banks (AABB) guidelines.